The year-end report for 2022 shows a record for Miris' sales of analysis instruments that promote neonatal health. With a sales increase of 22 percent and gross margins of 75 percent, the medical technology company is well on its way to establishing Miris HMA as standard care for breast milk analysis. BioStock contacted CEO
Read the interview with Miris' CEO
https://www.biostock.se/en/2023/03/miris-reporting-record-sales/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
https://news.cision.com/miris-holding/r/biostock-miris-reporting-record-sales,c3726048
(c) 2023 Cision. All rights reserved., source